Logo featuring "BIOVECTRA" in purple text with a blue and yellow abstract design, and the phrase "A part of Agilent" below.
Facebook Linkedin

BIOREAGENTS CATALOGUE

Explore Superior Quality Bioreagents from BIOVECTRA

Click Graphic Below to View Catalogue

The image is a cover for the "Bioreagents Catalogue" by Biovectra, featuring a test tube graphic, "February 2024," and "Click Here" button.

Want to Learn More?

BIOVECTRA offers a comprehensive selection of bioprocessing reagents and diagnostic & molecular biology reagents—like DTT, DHAA, TCEP, and more—to meet the demands of research, testing, and large-scale manufacturing. Designed to deliver exceptional performance and reliability, our reagents provide the foundation for advancing your bioprocessing and diagnostic capabilities.

Why BIOVECTRA?
• Versatile Sizing Options: From gram-scale to multi-kg quantities
• Diverse Grades Available: Including cGMP to meet regulatory requirements
• State-of-the-Art Facilities: North American-based synthesis facility with flexible reactor scales (50-1,000 gallons)
• Uncompromising Quality: Stringent manufacturing standards for purity, consistency, and performance

At BIOVECTRA, we are committed to delivering reagents that empower innovation across research, diagnostics, and manufacturing operations. Trust our expertise to support your projects with unmatched quality and reliability.

Submit this form to have a representative reach out and share more. 

© BIOVECTRA 2024. All rights reserved

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors